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See Article, pages 82–88This issue of the Journal of Hepatology contains a very interesting
and provocative study by Yin et al. that will undoubtedly
generate signiﬁcant debate in the hepatocellular carcinoma
(HCC) community [1]. The authors have to be commended for
performing a well-designed trial to determine whether resection
or trans-arterial chemo-embolization (TACE) yields better
outcomes in patients with BCLC stage B HCC.
The current European Association for Study of the Liver
(EASL) and American Association for the Study of Liver Disease
(AASLD) guidelines recommend resection as the primary treat-
ment for HCC in patients with a single tumor, Child class A liver
function with total bilirubin 61 mg/dl, no evidence of clinically
signiﬁcant portal hypertension, and excellent performance
status [2,3]. The criteria also require patients to have no
evidence of extra-hepatic disease or invasion of the portal or
hepatic veins on imaging.
These guidelines are essentially based on a study from 1999
that drew its conclusions from 77 patients undergoing hepatic
resection for HCC [4]. In addition, the guidelines are centered
on the concept of who would be ‘‘ideal’’ candidates for resection
thus yielding the highest survival for surgery as a treatment
modality. Likewise, the role of TACE for treatment of BCLC stage
B patients has been established by a randomized trial as well as
a meta-analysis comparing TACE to best supportive care and
not to other treatment modalities such as surgery [5,6].
The guidelines do not base their recommendations on
what treatment modality yields the best result in a particular
individual. Thus while a patient may not be an ideal candidate
for surgery, resection may still yield a better outcome than
the proposed BCLC treatment. We simply did not know because
there has been no data.
It is clear that, despite the lack of robust evidence, many
centers were already offering surgery to patients with BCLC stage
B and C tumors believing that resection yielded superior
outcomes to TACE and sorafenib [7]. While other studies have
attempted to compare resection to TACE, none have been con-
ducted in a manner that allowed for drawing robust conclusion
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Open access under CC BY-NC-ND license.The study by Yin et al.was conducted in a randomized fashion
with a well-deﬁned study population consisting of patients with
BCLC stage B tumors. They found that the patients treated
with resection had a median survival of 41 months, which was
signiﬁcantly longer when compared to 14 months for those
treated with TACE. Multivariate analysis identiﬁed the type of
treatment as an independently associated with survival with a
2.3 fold higher likelihood of mortality for patients treated with
TACE. The survival advantage of hepatic resection was observed
in patients with two tumors as well as those with more than
two cancers.
While the study was well constructed in terms of patient
selection and statistical methods, it will likely draw criticism
for the method of TACE which was used and the outcomes that
were achieved. The authors performed TACE using an emulsion
of 5-ﬂuorouracil, mitomycin C, cisplatin, and lipiodol followed
by Gelfoam particles and achieved a median survival of only
14 months. Trials from a decade ago using similar techniques
achieved median survivals closer to 20 months [5,11]. In addition,
many centers are currently using drug-eluting particles loaded
with adriamycin with some publications reporting a median sur-
vival of up to 40 months in BCLC stage B patients [12]. However,
readers should be reminded of the fact that the average size of
the tumors treated by TACE in the study by Yin et al. was
7.4 cm, substantially larger than the average tumor size reported
in other manuscripts. In fact, the Liver Cancer Study Group of
Japan reported a 1.95 fold increase in mortality when treating
tumors >5 cm using TACE [13]. Likewise, treating multiple
tumors was also associated with a hazard ration of 1.3. Thus, in
the context of the size and number of tumors treated, the
outcomes after TACE may, in fact, be quite appropriate.
In summary, the study by Yin et al. provides sorely needed
data that helps to answer the question ‘‘What treatment yields
the best outcome for patients with BCLC stage B HCC?’’ Until
now, we have only known that TACE yields longer survival than
best supportive care for these patients. For the ﬁrst time, a
well-conducted randomized trial suggests that surgery may yield
better results than TACE. This study will likely generate signiﬁ-
cant debate as it challenges our current concepts regarding the
relative role of surgery for patients who are not considered
‘‘ideal’’ candidates. However, we must remember to keep our
minds open to theories and data that challenge our existing
mindset and realize that guidelines are not ‘‘carved in stone’’
and are meant to be modiﬁed as new data comes to light.14 vol. 61 j 3–4
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